| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8603763 | The American Journal of Medicine | 2018 | 35 Pages |
Abstract
Addition of the dipeptidyl peptidase-4 inhibitor alogliptin to dual therapy with metformin plus sulfonylurea significantly reduced HbA1c and was well tolerated. Lower mortality rates were seen in patients treated with alogliptin in this subgroup.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
William B. MD, Simon R. MD, Christopher P. MD, Heena BSc, Kamlesh MD, Richard M. MD, EXAMINE Investigators EXAMINE Investigators,